Adjuvant therapy with high dose vitamin D following primary treatment of melanoma at high risk of recurrence: a placebo controlled randomised phase II trial (ANZMTG 02.09 Mel-D)

BACKGROUND: Patients with primary cutaneous melanomas that are ulcerated and >2 mm in thickness, >4 mm in thickness and those with nodal micrometastases at diagnosis, have few options for adjuvant treatment. Recent studies have suggested a role for vitamin D to delay melanoma recurrence and im...

Descripción completa

Detalles Bibliográficos
Autores principales: Saw, Robyn PM, Armstrong, Bruce K, Mason, Rebecca S, Morton, Rachael L, Shannon, Kerwin F, Spillane, Andrew J, Stretch, Jonathan R, Thompson, John F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221702/
https://www.ncbi.nlm.nih.gov/pubmed/25343963
http://dx.doi.org/10.1186/1471-2407-14-780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221702/
https://www.ncbi.nlm.nih.gov/pubmed/25343963
http://dx.doi.org/10.1186/1471-2407-14-780

Ejemplares similares